Salvage Chemotherapy With Docetaxel, Oxaliplatin and Gemcitabine in Platinum-Pretreated Advanced Epithelial Ovarian Cancer - Results of a Phase Ii Study

Seliger, G; Mueller, Lutz Peter; Buechele, T.; Kellner, O.; Grothey, Axel; Strauß, Hans; Schmoll, Hans Joachim; Koelbl, Heinz

doi:10.1136/ijgc-00009577-200303001-00047

Search citation statements

Order By: Relevance

Paper Sections

Select...

Oxaliplatin Plus Docetaxel and Gemcitabine1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2006

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This regimen elicited a CR of 9.5% and a PR of 48% with a median PFS duration of 2.7 months and an OS duration of 17.2 months (71) . Patients tolerated treatment without severe toxicity.…”

Section: Oxaliplatin Plus Docetaxel and Gemcitabinementioning

confidence: 99%

Clinical application of oxaliplatin in epithelial ovarian cancer

Fu¹,

Kavanagh²,

Hu³

et al. 2006

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

Platinum remains the most active drug class in ovarian cancer treatment; however, new single-agent and combination therapies are needed to improve the clinical outcome of ovarian cancer therapies. Oxaliplatin, a third-generation platinum derivative, has shown effective antitumor activity and a favorable toxicity profile in epithelial ovarian cancer. Preclinical evidence of the synergistic cytotoxic effect of oxaliplatin in combination with several other chemotherapeutic agents and clinical evidence of the absence of any dose-limiting hematologic toxicity associated with this agent have made oxaliplatin an attractive compound for combination agent therapy. This article reviews the current status of the clinical application of oxaliplatin alone and in a combination regimen in epithelial ovarian cancer treatment.

show abstract

“…This regimen elicited a CR of 9.5% and a PR of 48% with a median PFS duration of 2.7 months and an OS duration of 17.2 months (71) . Patients tolerated treatment without severe toxicity.…”

Section: Oxaliplatin Plus Docetaxel and Gemcitabinementioning

confidence: 99%